As populations age and osteoarthritis becomes an increasingly common burden on healthcare systems worldwide, minimally invasive joint treatments are gaining significant traction among both clinicians and patients. A detailed viscosupplementation market report values the global industry at USD 3,275.4 million in 2023, with projections indicating growth to USD 5,938.3 million by 2031 at a CAGR of 7.91%. This expansion reflects the treatment’s growing role as a preferred non-surgical intervention for patients seeking relief from joint pain without the risks and lengthy recovery associated with surgical alternatives.
Understanding Viscosupplementation
Viscosupplementation involves replacing synovial fluid in affected joints with a hyaluronate solution possessing viscous properties similar to natural synovial fluid. Primarily used to manage osteoarthritis in joints such as the knee, hip, or shoulder, the treatment relies on hyaluronic acid — a naturally occurring substance found in joint fluid and cartilage — to cushion and lubricate joints, providing relief from pain and stiffness. The procedure, typically performed by a trained healthcare provider under sterile conditions, is generally recommended for patients who have not responded adequately to conventional therapies such as pain medication or physical therapy.
Osteoarthritis Prevalence: The Core Growth Driver
The rising global incidence of osteoarthritis remains the single most significant driver behind viscosupplementation market growth. As a chronic condition predominantly affecting individuals aged 30 and above, osteoarthritis has the potential to progress into a disabling condition that imposes substantial burdens on both affected individuals and broader healthcare systems. Projections suggest that by 2050, roughly one million people will be living with the condition, a trajectory that underscores the pressing need for effective, accessible treatment methods such as viscosupplementation.
This expansion is further reinforced by the aging global population and increasingly sedentary lifestyles that contribute to conditions such as diabetes, which in turn elevate osteoarthritis risk. Together, these demographic and lifestyle trends are creating sustained, structural demand for joint treatment solutions that extends well beyond short-term market cycles.
Cost Barriers and Reimbursement Challenges
Despite strong underlying demand, the viscosupplementation market faces meaningful headwinds related to the high cost of treatment and complex reimbursement policies surrounding drug approval. These financial and regulatory barriers can limit patient access, particularly in markets where healthcare coverage for elective or non-surgical joint treatments remains inconsistent. In response, manufacturers are focusing on innovation aimed at improving cost-effectiveness and clinical value, while favorable government initiatives and growing awareness of osteoarthritis treatment options are expected to help offset some of these access challenges over the forecast period.
The Shift Toward Personalized and Non-Surgical Care
One of the clearest trends shaping the viscosupplementation landscape is the accelerating shift toward personalized medicine. Healthcare providers are increasingly recognizing the importance of individualized care tailored to factors such as patient age, disease severity, comorbidities, and lifestyle — a shift that is driving development of customized viscosupplementation regimens designed to meet the specific needs of each patient. Advancements in biomarker research and diagnostic imaging are further supporting this transition by enabling more accurate disease characterization and better prediction of treatment response.
This personalization trend is closely intertwined with the broader growth of non-surgical treatment preference. As patients increasingly seek to avoid the risks and extended recovery timelines associated with surgery, viscosupplementation’s status as a minimally invasive intervention has made it an increasingly attractive option, particularly as clinical evidence continues to demonstrate its effectiveness for knee osteoarthritis specifically.
Segment Analysis: Three-Injection Products and Orthopedic Clinics Lead
By product, three-injection formulations led the market in 2023, reaching a valuation of USD 1,409.6 million. These procedures are widely favored by medical professionals, particularly in the context of avoiding total knee replacement surgery for osteoarthritis patients, owing to their demonstrated efficacy. Continued advancement in medical technology, along with positive outcomes from numerous clinical trials, continues to reinforce three-injection procedures as a significant component of the broader osteoarthritis treatment landscape, further supported by ongoing R&D investment aimed at improving patient outcomes.
By end-user, orthopedic clinics and ambulatory surgical centers (ASCs) secured the largest revenue share at 65.59% in 2023. The growing prevalence of ASCs within the broader healthcare delivery ecosystem reflects a wider industry shift toward efficient outpatient surgical care, encompassing procedures ranging from knee and hip replacement to ACL and shoulder surgery — many of which can now be performed within a single day with minimal or no hospitalization required, reducing both healthcare costs and patient inconvenience.
Regional Analysis: Asia-Pacific Leads, Europe Poised for Rapid Growth
Asia-Pacific held the largest regional share in 2023, at approximately 45.12% of the global market, equivalent to USD 1,477.9 million. Contributing factors include an aging population, rising lifestyle disease prevalence, and improving healthcare infrastructure, all of which have contributed to increasing rates of knee osteoarthritis and, correspondingly, growing adoption of viscosupplementation as a non-surgical treatment option. Countries including China, India, Japan, and South Korea continue to demonstrate strong and growing demand, supported by economic development, expanding medical tourism, and the presence of leading manufacturers developing cost-effective viscosupplements tailored to local market needs.
Europe is projected to be the fastest-growing region, with a CAGR of 9.26% through the forecast period. The regional market is expected to witness a notable shift from multiple-injection treatment cycles toward single-injection alternatives, driven by the convenience and improved patient compliance associated with fewer treatment visits. Regional medical organizations focused on osteoarthritis and osteoporosis continue to play an important role in disseminating clinical and economic information among practitioners, further supporting coordinated regional market growth.
Competitive Landscape and Recent Developments
The viscosupplementation market remains fragmented, with prominent players pursuing partnerships, mergers, acquisitions, and product innovation to strengthen their competitive position. Recent developments include funding secured for an injectable therapeutic targeting knee osteoarthritis progression, reflecting continued investor confidence in next-generation treatment approaches. In a separate development, an Italian pharmaceutical company specializing in bone and joint disorders announced a significant acquisition of a Switzerland-based prescription medication developer, a move aimed at broadening its portfolio and strengthening its position within the broader musculoskeletal treatment sector.
Key companies shaping the competitive landscape include Sanofi S.A., Zimmer Biomet, Bioventus, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Johnson & Johnson Medtech, OrthogenRx, Inc., and Chugai Pharmaceutical Co., Ltd., among others.
Outlook
With three-injection products projected to retain the largest share at USD 2,566.5 million by 2031, and Europe’s market value forecast to reach USD 1,487.5 million, the viscosupplementation market appears set for sustained expansion. As osteoarthritis prevalence continues to climb globally and healthcare systems increasingly prioritize minimally invasive, personalized treatment approaches, viscosupplementation is likely to remain a cornerstone therapy within the broader orthopedic and musculoskeletal care landscape for years to come.
